$10.63
0.56% yesterday
Nasdaq, Nov 06, 10:01 pm CET
ISIN
US30049G1040
Symbol
EVOK

Evoke Pharma, Inc. Stock price

$10.63
+5.95 127.14% 1M
+7.33 222.12% 6M
+6.21 140.50% YTD
+4.79 82.02% 1Y
-9.53 47.27% 3Y
-520.73 98.00% 5Y
-519.29 97.99% 10Y
-1,679.93 99.37% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-0.06 0.56%
ISIN
US30049G1040
Symbol
EVOK
Industry

Key metrics

Basic
Market capitalization
$16.6m
Enterprise Value
$9.5m
Net debt
positive
Cash
$12.1m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.0
EV/Sales
0.7 | 0.6
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
40.2%
Return on Equity
-76.1%
ROCE
-120.3%
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$12.8m | $16.1m
EBITDA
- | -
EBIT
$-5.3m | $-5.0m
Net Income
$-5.4m | $-3.0m
Free Cash Flow
$-3.6m
Growth (TTM | estimate)
Revenue
70.1% | 57.4%
EBITDA
- | -
EBIT
14.0% | 3.3%
Net Income
17.5% | 44.3%
Free Cash Flow
34.8%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
- | -
EBIT
-41.7%
Net
-42.1% | -18.5%
Free Cash Flow
-28.3%
More
EPS
$-2.1
FCF per Share
$-2.4
Short interest
1.3%
Employees
3
Rev per Employee
$3.4m
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
13 13
70% 70%
100%
- Direct Costs 0.43 0.43
95% 95%
3%
12 12
69% 69%
97%
- Selling and Administrative Expenses 18 18
31% 31%
138%
- Research and Development Expense 0.06 0.06
100% 100%
0%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.34 -5.34
14% 14%
-42%
Net Profit -5.38 -5.38
17% 17%
-42%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Neutral
PRNewsWire
3 days ago
MILWAUKEE , Nov. 4, 2025 /PRNewswire/ -- The Ademi Firm is investigating Evoke (NASDAQ: EVOK) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Neutral
Business Wire
3 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fair to Evoke shareholders. Halper Sadeh encourages Evoke shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or s...
Neutral
Business Wire
4 days ago
CLEVELAND--(BUSINESS WIRE)--Partnership creates national RIA with 600 employees and $65 billion in AUM.
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today